FIG 3.
Platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor (PARPi) progression. (A) Time on treatment on PARPi (blue) and subsequent platinum-based chemotherapy (orange), which did not necessarily occur immediately after PARPi therapy. Best radiographic and prostate-specific antigen (PSA) responses are summarized in the table. Zygosity status for the DNA damage repair gene is indicated. Three of 7 evaluable patients had RECIST 1.1 stable disease (SD) or partial response (PR) on platinum-based chemotherapy. (B) Six of 7 evaluable patients had PSA decrease on platinum therapy, with 2 BRCA2-altered patients achieving a 50% prostate-specific antigen decline from baseline response. (C) One patient with a BRCA1 germline mutation had a RECIST PR on platinum chemotherapy after progression on a PARPi, with representative 18F-labeled fluorodeoxyglucose–positron emission tomography/computed tomography images. This patient was taxane naïve and received carboplatin with docetaxel; therefore, his response cannot be definitely attributed to the platinum agent alone. HOMDEL, homozygous deletion; N/A, not evaluable; PD, progression of disease; PR, partial response; SD, stable disease.